Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab, Rintatolimod, and Cisplatin in Recurrent Ovarian Cancer
NCT03734692Phase 2Active, not recruiting
- Start
- Jan 2019
- Primary completion
- Jul 2024
- Modality
- Antisense DNA, Immune Checkpoint Inhibitors, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
A Phase 2 trial of rintatolimod, pembrolizumab in ovarian cancer. Started Jan 2019; status: active, not recruiting.
02
Drugs
rintatolimodpembrolizumab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT03734692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03734692.